POINT Biopharma Global, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating POINT (Nasdaq: PNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.

In the transaction, POINT stockholders are expected to receive only $12.50 per share in cash (an aggregate of approximately $1.4 billion). The transaction agreement unreasonably limits competing transactions for POINT by imposing a significant penalty if POINT accepts a competing bid. POINT insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of POINT’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.